These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
101 related articles for article (PubMed ID: 16876918)
1. [Urinary erythropoietin excretion: an unknown cause of anemia during nephrotic syndrome]. Terrier B; Fakhouri F; Sultanik P; Delarue R; Hummel A Rev Med Interne; 2006 Aug; 27(8):643-5. PubMed ID: 16876918 [TBL] [Abstract][Full Text] [Related]
2. Treatment of anemia of nephrotic syndrome with recombinant erythropoietin. Gansevoort RT; Vaziri ND; de Jong PE Am J Kidney Dis; 1996 Aug; 28(2):274-7. PubMed ID: 8768925 [TBL] [Abstract][Full Text] [Related]
3. Plasma concentration and urinary excretion of erythropoietin in adult nephrotic syndrome. Vaziri ND; Kaupke CJ; Barton CH; Gonzales E Am J Med; 1992 Jan; 92(1):35-40. PubMed ID: 1731507 [TBL] [Abstract][Full Text] [Related]
4. Successful erythropoietin treatment for severe anemia in nephrotic syndrome without renal dysfunction. Ishimitsu T; Ono H; Sugiyama M; Asakawa H; Oka K; Numabe A; Abe M; Matsuoka H; Yagi S Nephron; 1996; 74(3):607-10. PubMed ID: 8938689 [TBL] [Abstract][Full Text] [Related]
6. Anemia in nephrotic syndrome: approach to evaluation and treatment. Iorember F; Aviles D Pediatr Nephrol; 2017 Aug; 32(8):1323-1330. PubMed ID: 27999949 [TBL] [Abstract][Full Text] [Related]
7. Successful treatment of anaemia of nephrotic syndrome with recombinant human erythropoietin. Bayés B; Serra A; Juncà J; Lauzurica R Nephrol Dial Transplant; 1998 Jul; 13(7):1894-5. PubMed ID: 9681764 [No Abstract] [Full Text] [Related]
8. Erythropoietin and transferrin metabolism in nephrotic syndrome. Vaziri ND Am J Kidney Dis; 2001 Jul; 38(1):1-8. PubMed ID: 11431174 [TBL] [Abstract][Full Text] [Related]
9. Erythropoietin deficiency causes anemia in nephrotic children with normal kidney function. Feinstein S; Becker-Cohen R; Algur N; Raveh D; Shalev H; Shvil Y; Frishberg Y Am J Kidney Dis; 2001 Apr; 37(4):736-42. PubMed ID: 11273873 [TBL] [Abstract][Full Text] [Related]
10. Effect of human erythropoietin (hEPO) treatment on anemia in ICR-derived glomerulonephritis (ICGN) mice. Miyamoto Y; Kuramitsu-Miyamoto K; Iwanaga E; Uchio-Yamada K; Yamaguchi-Yamada M; Ogura A; Manabe N Exp Anim; 2005 Apr; 54(2):181-4. PubMed ID: 15897628 [TBL] [Abstract][Full Text] [Related]
11. Therapy-resistant anaemia in congenital nephrotic syndrome of the Finnish type--implication of EPO, transferrin and transcobalamin losses. Toubiana J; Schlageter MH; Aoun B; Dunand O; Vitkevic R; Bensman A; Ulinski T Nephrol Dial Transplant; 2009 Apr; 24(4):1338-40. PubMed ID: 19153070 [TBL] [Abstract][Full Text] [Related]
12. Simultaneous improvement of minimal-change nephrotic syndrome and anemia with steroid therapy. Yabana M; Kihara M; Toya Y; Tamura K; Matsumoto K; Takagi N; Kamijo S; Ishii M; Umemura S Nephron; 1999 Jan; 81(1):84-8. PubMed ID: 9884426 [TBL] [Abstract][Full Text] [Related]
13. Effect of erythropoietin on urinary liver-type fatty-acid-binding protein in patients with chronic renal failure and anemia. Nakamura T; Sugaya T; Kawagoe Y; Suzuki T; Ueda Y; Koide H Am J Nephrol; 2006; 26(3):276-80. PubMed ID: 16772708 [TBL] [Abstract][Full Text] [Related]
14. Suppressed serum erythropoietin response to anemia and the efficacy of recombinant erythropoietin in the anemia of rheumatoid arthritis. Takashina N; Kondo H; Kashiwazaki S J Rheumatol; 1990 Jul; 17(7):885-7. PubMed ID: 2213753 [TBL] [Abstract][Full Text] [Related]
15. Excessive level of parathyroid hormone may induce the reduction of recombinant human erythropoietin effect on renal anemia. Fujita Y; Inoue S; Horiguchi S; Kuki A Miner Electrolyte Metab; 1995; 21(1-3):50-4. PubMed ID: 7565462 [TBL] [Abstract][Full Text] [Related]
16. Comparison of two recombinant erythropoietin formulations in patients with anemia due to end-stage renal disease on hemodialysis: a parallel, randomized, double blind study. Pérez-Oliva JF; Casanova-González M; García-García I; Porrero-Martín PJ; Valenzuela-Silva CM; Hernández-Montero T; Lagarde-Ampudia M; Casanova-Kutsareva Y; Avila-Albuerne Y; Vargas-Batista A; Bobillo-López H; Herrera-Valdés R; López-Saura PA; BMC Nephrol; 2005 May; 6():5. PubMed ID: 15910687 [TBL] [Abstract][Full Text] [Related]
17. Clinical efficacy of recombinant human erythropoietin in the treatment of anemia in hemodialysis patients: influence of dosing regimen, iron status, and serum aluminum. Tsai JC; Lai YH; Tsai ZY; Chien LJ; Tsai JH Gaoxiong Yi Xue Ke Xue Za Zhi; 1991 Mar; 7(3):126-35. PubMed ID: 1865507 [TBL] [Abstract][Full Text] [Related]
18. [Does long-term erythropoietin therapy influence the prevalence of serum markers of hepatitis B and C in haemodialysed uraemic patients?]. Mesjasz J; Wiecek A; Gonciarz Z; Mazur W; Kokot F Pol Merkur Lekarski; 2004 Apr; 16(94):362-7. PubMed ID: 15517934 [TBL] [Abstract][Full Text] [Related]
19. Chronic occult intra-alveolar hemorrhage: a rare cause of failure to respond to erythropoietin. Conlon PJ; O'Neill S; O'Neill G; Kelly F; Donohoe J Clin Nephrol; 1994 Feb; 41(2):83-5. PubMed ID: 8004833 [TBL] [Abstract][Full Text] [Related]
20. Treatment of the anemia with human recombinant erythropoietin in CAPD patients. Miranda B; Selgas R; Riñon C; Fernandez-Zamorano A; Borrego F; Ortuño F; Lopez-Revuelta K; Torre A; Sanchez Sicilia L Adv Perit Dial; 1990; 6():296-301. PubMed ID: 1982831 [TBL] [Abstract][Full Text] [Related] [Next] [New Search]